SKN | SpyGlass Pharma Sets Terms for $150 Million IPO in Chronic Eye Disease Market Debut
SpyGlass Pharma, a biotech company focused on treatments for chronic eye conditions, has set the terms for a planned $150 million initial public offering,...
SKN | Xsolla SPAC 1 Prices Downsized $200 Million IPO as Gaming-Focused Deal Tests SPAC Appetite
Xsolla SPAC 1, a special purpose acquisition company backed by executives from video game fintech firm Xsolla, has priced a downsized $200 million initial...
SKN | Belgian Fibrotic Disease Biotech AgomAb Therapeutics Sets Terms for $200 Million US IPO
AgomAb Therapeutics, a Belgian biotechnology company developing treatments for fibrotic diseases, has set terms for a planned $200 million initial public offering in the...
SKN | Seagate Shares Hit Record High as AI Storage Boom Drives Earnings Re-Rating
Seagate Technology Holdings plc surged to an all-time high following a strong quarterly earnings report that reinforced investor confidence in the company’s exposure to...
SKN | Hair Loss Biotech Veradermics Sets Terms for $200 Million IPO
Veradermics, a clinical-stage biotechnology company focused on treatments for hair loss and dermatological conditions, has set terms for a $200 million initial public offering...